Slide 1: Fourth Quarter 2021 Operating & Financial Results Conference Call
Fourth quarter 2021 Operating & Financial Results Conference Call / Webinar March 10th, 2022 4:30 PM Eastern Time NASDAQ:LTRN
Slide 2: Today's Speakers
TODAY’S SPEAKERS Panna Sharma David Margrave Dr. Kishor Bhatia Nicole Leber Chief Executive Officer, Chief Financial Officer Chief Scientific Officer Investor Relations President and Director and Secretary NASDAQ:LTRN 1
Slide 3: Forward Looking Statements
LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 4: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A NASDAQ:LTRN NASDAQ:LTRN 3
Slide 5: RADR Surpassed 18 Billion Datapoints This Past Month
RADR® Surpassed 18 billion datapoints this past month NEW CANCER CATEGORIES • Rare Solid Tumors NEW CANCER CATEGORIES • Ultra Rare Cancers • Pediatric Cancers • Bladder Cancer • Immune Data • CNS & Brain Cancers • Protein Data • Hotspot Mutation Panels • Methylome Data • Epigenetic Data NEW DATA TYP
Slide 6: Expanding RADR drives growth in our portfolio and collaborations
Expanding RADR® drives growth in our portfolio of therapies and potential collaborations with other biopharma companies RADR® Surpassed 18 Billion Datapoints • Accelerate drug development timelines • Develop insights into the creation of combination-therapy programs • Uncover new therapeutic opportu
Slide 7: What is RADR
What is RADR ® Response Algorithm for A proprietary integrated data analytics, experimental biology, oncology-focused, machine-learning-based platform Drug Positioning & Rescue focused on drug development Leverages cutting edge machine-learning approaches and techniques to generate powerful data-dri
Slide 8: Lantern leverages A.I. to reduce oncology drug development costs
Lantern leverages A.I. to reduce oncology drug development costs and improve the likelihood of success Abandoned Drug Assets & New Drug Development RADR® Responders Non-Responders • Drugs that fell short of statistical • Big data (genomic, clinical, response) • Patient stratification based on A.I. e
Slide 9: How RADR is used by Lantern & our collaborators
How RADR® is used by Lantern & our collaborators RADR can derive Machine Identify and prioritize Use RADR to find potential Learning based gene signatures, Use different algorithms and type/subtype of cancer for Mechanism of Action (MoA) which can guide biomarker methods from RADR to find your compou
Slide 10: Lantern's unique & rapidly developing pipeline
Lantern’s unique & rapidly developing pipeline Indication Program R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Initial 9 patients showed median (Metastatic Castration-Resistant Prostate Cancer) (Irofulven) overall survival (mOS) of 12.5 months Non-Small Cell Lung Cancer LP-300 T
Slide 11: Harmonic clinical trial – Phase 2 trial for LP-300
Harmonic™ clinical trial – Phase 2 trial for LP-300 “ If lung cancer in never-smokers were a separate entity, it would be in the top 10 cancers in the U.S. ” Harmonic™ clinical trial is a Phase 2, multi-center, study to evaluate Lantern’s investigational drug LP-300. It is focused on treating Never
Slide 12: LP-300 Phase II builds on prior Phase III subgroup survival benefit
Lantern’s precision oncology approach in the LP-300 Phase II trial builds on a prior Phase III trial that did not meet clinical efficacy endpoints but demonstrated survival benefit in a patient subgroup LP-300 + Cisplatin / Paclitaxel 72% Placebo + Cisplatin / Paclitaxel 125% increase 63% in 2 Year Su
Slide 13: Orphan Drug Designations for LP-184
• Granted Orphan Drug Designation for the treatment of Pancreatic Cancer, GBM and ATRT • Granted Rare Pediatric Disease Designation for the treatment of ATRT • Positive preclinical data for LP-184 in pancreatic cancer and GBM • Currently conducting IND enabling studies to support IND submission in 2
Slide 14: LP-184 Glioblastoma Multiforme (GBM)
LP-184 12,914 250,000 Glioblastoma Multiforme (GBM) Estimated new cases Estimated Global in the US in 2022 incidence in 2022 Recent Highlights Upcoming Milestones • In orthotopic GBM xenografts showed significant • Evaluation of in vivo anti-tumor efficacy of LP-184 + tumor reduction and survival bene
Slide 15: Positive preclinical data in GBM
Positive preclinical data in GBM In-vitro Blood Brain Permeability of LP-184 Combination Therapy of LP-184 with Spironolactone Tumor Volumes for CTG-1522 140% TGI with LP-184 treatment NASDAQ:LTRN 14
Slide 16: LP-184 Pancreatic Cancer
LP-184 37,700 460,000 Pancreatic Cancer Estimated new cases in the Estimated Global incidence US in 2021 in 2021 Recent Highlights Upcoming Milestones • In HR deficient pancreatic cancer cell line, LP-184 • Evaluation of in vivo anti-tumor efficacy of LP-184 in combined with gemcitabine, irinotecan an
Slide 17: Positive preclinical data in pancreatic cancer
Positive preclinical data in pancreatic cancer LP-184 in vivo response in a Capan-1 LP-184 demonstrated significant tumor shrinkage (146x) in pancreatic cancer xenograft mouse model in-vivo mice PDX models 600 Vehicle control LP-184 (3 mg/ kg) Tumors From 500 Vehicle Control Mice at the End 400 of S
Slide 18: LP-184 synergistic combinations in pancreatic cancer cell lines
LP-184 synergistic combinations in pancreatic cancer cell lines LP-184 Cell line NERD HRD Bliss Synergy Score + combination agent Capan1 No Yes Gemcitabine 13.76 5-Fluorouracil 10.53 Irinotecan 16.50 Oxaliplatin 15.42 Panc03.27 No No Irinotecan 12.00 Oxaliplatin 12.09 Note: Bliss synergy score range
Slide 19: LP-184 Atypical Teratoid Rhabdoid Tumor (ATRT)
LP-184 60 600 Atypical Teratoid Rhabdoid Estimated new cases Total existing cases Tumor (ATRT) in the US annually of ATRT in the US Recent Highlights Upcoming Milestones • LP-184 for ATRT granted Orphan Drug Designation • Publications showing enhanced LP-184 response with and Rare Pediatric Disease
Slide 20: LP-184 is effective in a xenograft model of ATRT
LP-184 is effective in a xenograft model of Atypical Teratoid / Rhabdoid Tumor (ATRT) CHLA06 subcutaneous cell line derived xenograft model (SMARCB1 deletion, MYC elevation) Tumor Volumes for CHLA-06 Representative terminal tumors Vehicle Control LP-184 4mg/kg Orphan Drug Designation (ODD) and Rare
Slide 21: ADC Program
ADC Program Antibody Drug Conjugate (ADC) Program for Select Solid Tumors Characteristics High Specificity Growing ADCs take advantage of the high potency of cytotoxic payloads and the 2 of the 4 largest oncology licensing deals in 2020 were for ADC assets superior specificity of antibodies. The dru
Slide 22: Academic and research collaborations
Academic and research collaborations LP-184 Gene signature development and drug sensitivity prediction LP-284 LP-184 Evaluation of efficacy of LP-184 in glioblastoma (GBM) LP-184 Determination of drug efficacy in pancreatic PDX tumor models Evaluation of drug efficacy and sensitivity in prostate and
Slide 23: Technology collaborations with Deep Lens and Code Ocean
Technology collaborations with Deep Lens and Code Ocean Strategic collaboration to accelerate Strategic collaboration to to facilitate the patient enrollment for the Harmonic™ accelerated development of RADR® Clinical Trial for never-smokers with non- while reducing development complexity small cell
Slide 24: Solid financial position will fuel continued growth
“ We believe our solid financial position will fuel continued growth and evolution of our RADR® A.I. platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted product and collaboration opportunities in a capital efficient
Slide 25: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A NASDAQ:LTRN 24
Slide 26: Summary results of operations
Summary results of operations Three Months Ended Year Ended December 31, December 31, (Unaudited) 2021 2020 2021 2020 Operating expenses: General and administrative 1,348,983 1,547,675 5,020,928 3,664,965 Research and development 2,162,260 1,348,329 7,570,580 2,243,225 Total operating expenses 3,511
Slide 27: Balance sheet highlights & summary
Balance sheet highlights & summary 12/31/2021 12/31/2020 Cash and Marketable Securities $ 70,725,447 $ 19,229,232 Prepaid Expenses & Other Current Assets $ 1,990,953 $ 1,007,690 Total Assets $ 73,950,477 $ 20,359,634 Total Liabilities $ 2,379,057 $ 660,839 Total Stockholders’ Equity $ 71,571,420 $ 1
Slide 28: Shares Outstanding
Shares Outstanding December 31, 2021 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 11,088,835 Warrants 273,777 Options (Employees, Management and Directors) 890,826 Fully Diluted Shares Outstanding 12,253,438 NASDAQ:LTRN 27
Slide 29: Share repurchase program
Share repurchase program $7,000,000 is authorized for share repurchase under the Company’s share repurchase program implemented in 2021 Shares Total Paid Date Average Price Repurchased including Commissions FY 2021 121,490 $7.71 $939,666 January 1, 2022 – March 1, 2022 308,345 $6.97 $2,199,964 Total
Slide 30: Migrating to a hybrid work environment
Migrating to a hybrid work environment HYBRID WORK GROWING ENVIRONMENT TEAM NASDAQ:LTRN 29
Slide 31: Contents
Contents Contents 01 Lantern Highlights 01 Lantern Highlights 02 Financial Overview 02 Financial Overview 03 R&D Updates 03 R&D Updates 04 Q&A 04 Q&A NASDAQ:LTRN 30 28
Slide 32: LP-184 shows exquisite sensitivity in NERD as well as HRD cancers
LP-184 shows exquisite sensitivity in NERD as well as HRD cancers ! LP-184 in NERD cancers LP-184 in HRD cancers wildtype – normal cell mutant 1 mutant 2 mutant 3 Mutant cell lines deficient in the Nucleotide Excision LP-184 treatment resulted in complete tumor regression Repair (NER) pathway were m
Slide 33: LP-284 Mantle Cell Lymphoma
LP-284 4,200 14,000 Mantle Cell Lymphoma 2014 Estimated 2017 estimated Global new cases in the US incidence number Recent Highlights Upcoming Milestones • Showed nanomolar potency in a variety of • Investigate LP-284’s potency in in vivo Mantle Cell hematological cancer cells including in mantle cel
Slide 34: LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells
LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells LP - 284 • LP-284 is a synthetic molecule belonging to the new generation of acylfulvenes, a family of naturally derived anti-cancer drug candidates. • LP-284 is the stereoisomer (enantiomer) of LP-184. LP-284 exhibited nan
Slide 35: 2022 Objectives
2022 Objectives A Transformational year for Lantern ● Launch of The Harmonic™ Trial - Ph. 2 clinical trial for LP-300 in NSCLC ● Advance LP-100 clinical trial ● Launch Ph. 1 clinical trial for LP-184 in genomically-defined solid tumors ● Launch Ph. 1/2 clinical trial for LP-184 in GBM ● Progress LP-
Slide 36: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A NASDAQ:LTRN 35
Slide 37: Contact: www.lanternpharma.com
www.lanternpharma.com @LanternPharma Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ:LTRN